Clinical trials: HFpEF - Heart Failure With Preserved Ejection Fraction
Heart Failure With Preserved Ejection Fraction
The Efficacy and Safety of Zhigancao Tang Granule for HFpEF of Qi-Yin Dificiency
This study was designed as a randomized, double blinded and placebo-controlled clinical trial. The aim of the study is to evaluate the efficacy and safety of Zhigancao Tang granule in patients with HFpEF of Qi-Yin dificiency.
- Trial name
- HFpEF (NCT04317339)
- Testing
- Zhigancao Tang granule
- Where
- China
- Volunteers
- 122 people
- Sponsor
- Shanghai University of Traditional Chinese Medicine
Heart Failure With Preserved Ejection Fraction (HFpEF)
Characteristics, Phenotypes, and TRAITS of Heart Failure With Preserved Ejection Fraction (TRAITS-HFpEF)
Heart failure with preserved ejection fraction (HFpEF), a certain type of heart failure, occurs when the heart doesn't pump blood around the body properly. It can cause breathlessness, tiredness, and swollen feet or ankles.
- Trial name
- TRAITS-HFpEF (NCT05383287)
- Where
- United Kingdom
- Volunteers
- 1,250 people
- Sponsor
- Manchester University NHS Foundation Trust
Heart Failure With Normal Ejection Fraction
Cell Therapy in HFpEF
The primary objective of the study is to investigate safety and efficacy of transendocardial CD34+ cell therapy in patients with HFpEF by evaluating changes in myocardial structure and function, patient exercise capacity and…
- Trial name
- CELLpEF (NCT02923609)
- Testing
- Cell Therapy
- Where
- Slovenia
- Volunteers
- 30 people
- Sponsor
- University Medical Centre Ljubljana
Heart Failure
EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)
This is a study in adults with chronic heart failure. People with chronic heart failure may need to be hospitalised for their condition. Some people with chronic heart failure may eventually die from their condition.
- Trial name
- NCT03057951
- Testing
- Empagliflozin
- Where
- 619 sites in United States, Argentina and 21 more
- Volunteers
- 5,988 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2, HFpEF - Heart Failure With Preserved Ejection Fraction
Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction
Investigators are building an empirical evidence base for real-world data through large-scale emulation of randomized controlled trials.
- Trial name
- DUP-TIRZSEMA (NCT06914141)
- Testing
- Tirzepatide, Semaglutide
- Where
- United States
- Volunteers
- 28,118 people
- Sponsor
- Brigham and Women's Hospital
Heart Failure
A Trial to Study Neladenoson Bialanate Over 20 Weeks in Patients With Chronic Heart Failure With Preserved Ejection Fraction
The objective of the study is to find the optimal dose of once daily oral neladenoson bialanate (BAY1067197) when given in addition to appropriate therapy for specific comorbidities.
- Trial name
- PANACHE (NCT03098979)
- Testing
- Neladenoson bialanate (BAY1067197)
- Where
- 76 sites in United States, Austria and 10 more
- Volunteers
- 305 people
- Sponsor
- Bayer
Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
HS235 Study in Overweight and Obese Participants With Combined Pre and Post-Capillary Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction
Study of HS235 in Overweight and Obese Participants with Combined Pre and Post-Capillary Pulmonary Hypertension due to Heart Failure with Preserved Ejection Fraction
- Trial name
- NCT07123779
- Testing
- HS235
- Where
- 3 sites in United States
- Volunteers
- 126 people
- Sponsor
- 35Pharma Inc., a GSK company
Heart Failure With Preserved Ejection Fraction, Type 2 Diabetes
Manganese-enhanced Magnetic Resonance Imaging (MEMRI) in Heart Failure With Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is a condition in which the heart cannot fill with blood effectively. As a result, people with HFpEF suffer fatigue, breathlessness, and develop swollen limbs.
- Trial name
- MEMRI in HFpEF (NCT06652763)
- Testing
- Minnesota Living with Heart Failure Questionnaire, Echocardiogram, Six-minute walk test
- Where
- United Kingdom
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Leicester
Heart Failure With Preserved Ejection Fraction
Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction
This study is to evaluate whether 16 weeks of treatment with IMR-687 is a safe and effective treatment for patients with Heart Failure with Preserved Ejection Fraction (HFpEF).
- Trial name
- SP9In-HFpEF (NCT05312021)
- Testing
- IMR-687
- Sponsor
- Cardurion Pharmaceuticals, Inc.
Heart Failure Preserved Ejection Fraction, Epicardial Adipose Tissue
Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction
This study seeks to develop improved cardiac MRI (CMR) methods to quantify epicardial adipose tissue (EAT) composition and to demonstrate the advantages of EAT composition imaging (a) in advancing the understanding of the…
- Trial name
- NCT07178145
- Testing
- GLP-1RA
- Where
- United States
- Volunteers
- 192 people
- Sponsor
- University of Virginia
HFpEF - Heart Failure With Preserved Ejection Fraction, Colchicine
Colchicine in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction
Heart failure with preserved left ventricular ejection fraction (HFpEF) is a syndrome associated with high morbidity and mortality rates.
- Trial name
- NCT05637398
- Testing
- Colchicine
- Where
- 2 sites in Russia
- Volunteers
- 42 people
- Sponsor
- I.M. Sechenov First Moscow State Medical University
Heart Failure, Crackles
Heart Failure Monitoring With Eko Electronic Stethoscopes
This proof-of-concept study will evaluate the feasibility of the Eko DUO to measure signals relevant to heart failure (HF) decompensation, as well as the feasibility to develop an algorithm to model hemodynamic filling pressures…
- Conditions
- Heart Failure, Crackles, Heart Failure With Preserved Ejection Fraction
- Trial name
- HOME0 (NCT04404452)
- Testing
- Use of Eko CORE and Eko DUO electronic stethoscopes
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Eko Devices, Inc.
HFpEF
Predictors of Poor Prognosis in HFpEF
Patients with HFpEF who have undergone meticulous clinical and instrumental evaluation (including diastolic exercise testing) between 2013 and 2020, will be followed up for at least 3 years.
- Trial name
- NCT06844032
- Where
- Russia
- Volunteers
- 500 people
- Sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
Heart Failure With Preserved Ejection Fraction
A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF)
This is a Phase 2 placebo-controlled study to evaluate the safety and tolerability of different doses of EDG-15400 in adults with heart failure with preserved ejection fraction (HFpEF).
- Trial name
- EQUINOX (NCT07795814)
- Testing
- EDG-15400 25 mg, EDG-15400 50 mg
- Where
- 28 sites in United States
- Volunteers
- 90 people
- Sponsor
- Edgewise Therapeutics, Inc.
Heart Failure
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure and Preserved Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-PRESERVED)
Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard diuretic and comorbidity treatment for heart…
- Trial name
- NCT01951638
- Testing
- Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg)
- Where
- 158 sites in United States, Australia and 23 more
- Volunteers
- 477 people
- Sponsor
- Bayer
Heart Failure With Preserved Ejection Fraction, Diabetes Mellitus, Type 2
Modulation of Circulating Levels of the Ketone Body 3-hydroxybutyrate in Patients With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction: Cardiovascular Effects.
Heart failure (HF) is among the most common causes of death in patients with type 2 diabetes (T2D). Ketones, 3-hydroxybutyrate (3-OHB), have shown to have beneficial hemodynamics effect in patients with hearth failure with…
- Conditions
- Heart Failure With Preserved Ejection Fraction, Diabetes Mellitus, Type 2, Ketonemia
- Trial name
- KETO-HFpEF (NCT05236335)
- Testing
- Ketone ester
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- University of Aarhus
Heart Failure, Congestive
Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a
Heart failure with preserved ejection fraction or HFpEF, represents nearly 50% of all heart failure cases and is particularly common in the elderly. The disease has no current treatment options.
- Trial name
- NCT02772068
- Testing
- Istaroxime, Exercise
- Where
- United States
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Benjamin Levine
Heart Failure With Preserved Ejection Fraction
Optimising CMR Scan Acquisitions for Novel Equipment/Sequences in Clinical Cardiovascular Populations.
The purpose of this study is to develop robust protocols for the optimisation of novel hardware, software and exercise equipment in the magnetic resonance imaging (MRI) environment in various cohorts with cardiovascular disease…
- Trial name
- OPTMISE-HFpEF (NCT06311552)
- Testing
- Participants will undergo a comprehensive CMR scan on either a 1.5- or 3-Tesla scanner
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- University of Leicester
Heart Failure With Preserved Ejection Fraction
BOOST: Blended Onsite and Offsite Structured Exercise Training and Coaching
Heart failure with preserved ejection fraction (HFpEF) represents a major public health burden that is both growing rapidly and has few effective therapies.
- Trial name
- HFpEF (NCT07413198)
- Testing
- multi-domain behavioral, coaching, and exercise protocol
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Wake Forest University Health Sciences
ST-Elevation Myocardial Infarction (STEMI), Heart Failure With Preserved Ejection Fraction (HFpEF)
Platelet Derived Growth Factor Receptor ß (PDGFRß) Imaging in Cardiac Fibrosis
An observational, cross-sectional, longitudinal, microdosing Position Emission Tomography (PET) imaging study to investigate platelet derived growth factor receptor beta (PDGFRß) expression in the heart of patients with high or…
- Trial name
- PARIS (NCT06956560)
- Testing
- PET/MRI or separate PET/CT and MRI
- Where
- Sweden
- Volunteers
- 30 people
- Sponsor
- Uppsala University